| Abstrakt: |
The patent application "Altering The Intestinal Microbiome In Cystic Fibrosis" explores the relationship between cystic fibrosis (CF) and changes in intestinal microbial communities. CF affects the gut environment, which in turn affects the growth of microbial communities. Treatments for CF, such as high-calorie diets and CFTR modulators, also impact the gut microbiota. The interaction between the gut microbiota and the host can have both positive and negative effects on lung health outcomes. The patent application proposes a method for reducing upper respiratory infections (URIs) in CF patients by analyzing their stool microbiota to identify high-risk patients and providing therapeutic interventions. These interventions can include altering the gut microbiome, using various medications, and implementing a computer-based system for identifying high-risk patients. [Extracted from the article] |
